The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline activity, and anticipated regulatory ...
GPC3, or Glypican-3, is an oncofetal glycoprotein tethered to the cell membrane via a glycophosphatidylinositol (GPI) anchor[1-2]. Its core protein comprises 580 amino acids and weighs in at 70 kDa.
NEW ORLEANS—A novel molecular imaging agent targeting glypican-3 (GPC3) has demonstrated high sensitivity and specificity in detecting hepatocellular carcinoma (HCC), including tumors smaller than one ...
Recent advancements in cancer immunotherapy have highlighted glypican-3 (GPC3) as a prominent target for treating hepatocellular carcinoma (HCC). However, approximately 10% to 30% of HCC patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results